PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1955066
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1955066
The global oncology positron emission tomography (PET) scan market was valued at USD 12.31 billion in 2025. The market is projected to grow from USD 13.03 billion in 2026 to USD 20.66 billion by 2034, exhibiting a CAGR of 5.93% during the forecast period (2026-2034).
North America dominated the global oncology PET scan market with a 52.40% market share in 2025, supported by advanced diagnostic infrastructure, high cancer prevalence, and strong adoption of innovative imaging technologies.
Oncology PET is a non-invasive molecular imaging technique widely used for cancer detection, staging, therapy assessment, and recurrence monitoring. Rising global cancer burden, increasing demand for diagnostic accuracy, technological advancements, and government-led cancer screening programs are key factors driving market growth.
Market Dynamics
Market Drivers
The rising global burden of cancer is a primary driver of market growth. Increasing incidence of cancers such as prostate, lung, breast, and colorectal cancer has led to a surge in screening programs and demand for advanced diagnostic tools. Governments and healthcare systems are investing heavily in early detection initiatives to reduce mortality and treatment costs.
For instance, updated imaging guidelines and approvals of novel PET imaging agents for prostate cancer have strengthened PET adoption. Additionally, the growing emphasis on personalized medicine and early diagnosis is accelerating the use of oncology PET scans across healthcare settings.
Market Restraints
The high cost of PET scanners and procedures remains a significant restraint. PET scanners can cost between USD 475,000 and over USD 750,000, excluding expenses related to installation, maintenance, radiotracers, and skilled personnel.
Inconsistent reimbursement policies further limit accessibility, particularly in developing economies. Even in developed markets, limited insurance coverage for repeat scans and certain oncology indications restricts utilization, negatively impacting market expansion.
Market Opportunities
The integration of artificial intelligence (AI) and advanced image quantification tools presents a major growth opportunity. AI-enabled PET systems improve lesion detection, tumor characterization, workflow efficiency, and treatment response evaluation.
Continuous innovation, regulatory approvals of AI-based software, and growing adoption of next-generation PET/CT systems are expected to support market development through 2034.
Market Challenges
Radiotracer availability and supply chain constraints pose critical challenges. Radiotracers such as FDG have short half-lives, requiring efficient logistics and proximity to cyclotron facilities. Delays or disruptions can lead to longer patient wait times and reduced scan volumes, limiting market growth.
Market Trends
Shift Toward Theranostics and Personalized Oncology Imaging
A key trend shaping the market is the growing adoption of theranostics, which combines diagnostics and targeted therapy. PET-based theranostic agents, especially PSMA-based tracers for prostate cancer, enable precise diagnosis and real-time therapy monitoring.
Increasing investments in personalized oncology imaging and the development of novel PET tracers are transforming cancer management and driving long-term market growth.
Impact of COVID-19
The COVID-19 pandemic significantly disrupted oncology PET services due to lockdowns and supply chain interruptions. Cancer screening and diagnostic procedures declined sharply, leading to delayed diagnoses.
According to global surveys, PET scan volumes dropped by over 65% in mid-2020, highlighting the pandemic's negative short-term impact. However, post-pandemic recovery and renewed focus on cancer diagnostics have restored market momentum.
By Source of Payment
The market is segmented into public and private health insurance/out-of-pocket. The private segment dominated the market due to faster access, premium-quality care, and reduced waiting times, especially in countries such as the U.S., Japan, India, and Brazil.
Public healthcare systems are also expanding PET access through increased funding and national cancer control programs.
By Service Provider
Based on service providers, the market includes hospitals, diagnostic centers, and others.
Competitive Landscape
Key players operating in the global oncology PET scan market include GE Healthcare, Siemens Healthcare Limited, Oncovision, Koninklijke Philips N.V., Canon Medical Systems, and Sonic Healthcare Limited. These companies focus on product innovation, strategic collaborations, and regulatory approvals to strengthen their market presence.
Conclusion
The global oncology positron emission tomography scan market is set to grow steadily from USD 12.31 billion in 2025 to USD 20.66 billion by 2034, driven by the rising cancer burden, technological advancements, and increasing focus on personalized oncology imaging. While high equipment costs and radiotracer supply challenges remain key concerns, innovations in AI-enabled imaging, theranostics, and expanding screening programs are expected to sustain long-term market growth. North America will continue to dominate the market, while Asia Pacific is anticipated to emerge as the fastest-growing region during the forecast period.
Segmentation By Source of Payment
By Service Providers
By Region